Peptide News Digest

#Bariatric-Surgery

3 stories

Research · View digest

JAMA Pediatrics Publishes UT Southwestern Retrospective Cohort Study Monday July 20, 2026 Analyzing 204,000+ US Adolescents and Young Adults Ages 13-25 Treated for Obesity Between May 2022 and January 2026 in the Epic Cosmos Electronic Health Record Database: GLP-1 Receptor Agonist Monotherapy Share Rose From 88.2% (May-November 2022) to 96.1% (June 2025-January 2026), Metabolic and Bariatric Surgery (MBS) Share Fell From 11.6% to 3.7% Over the Same Window, and Combined GLP-1 + MBS Use Remained Rare at Approximately 0.2%; Severe Obesity Currently Affects Approximately 9% of Ages 12-18 in the US

JAMA Pediatrics published a UT Southwestern Medical Center retrospective cohort study Monday July 20, 2026 examining GLP-1 receptor agonist and metabolic and bariatric surgery (MBS) utilization patterns among 204,000+ US adolescents and young adults ages 13-25 treated for obesity between May 2022 and January 2026 in the Epic Cosmos electronic health record database. Key findings: the share of patients using only GLP-1 drugs rose from 88.2% (May-November 2022) to 96.1% (June 2025-January 2026); the share of patients undergoing MBS fell from 11.6% to 3.7% over the same window; combined GLP-1 + MBS use remained rare at approximately 0.2%. The study documents a substitution effect from surgical obesity treatment toward pharmacologic obesity treatment in the youth population over 44 months of coverage. Context: severe obesity currently affects approximately 9% of US adolescents ages 12-18. The findings raise questions about long-term efficacy, weight-regain risk after GLP-1 discontinuation in adolescents, and the appropriate role of MBS in adolescents whose obesity is unresponsive to GLP-1 pharmacotherapy. The study covers the pediatric analog of the earlier adult utilization-shift patterns already documented in the Kaiser Permanente and Optum electronic health record data.

Research · View digest

AGA Gastroenterology Republishes POWER Framework June 19, 2026 — Multidisciplinary Obesity-Care Model Integrating GLP-1 Medications, Endoscopic Therapies, and Bariatric Surgery as Complementary Tools

The American Gastroenterological Association published a commentary in its journal Gastroenterology on June 19, 2026 revisiting and updating the influential POWER (Practice Guide on Obesity and Weight Management, Education, and Resources) framework, originally introduced in 2017. The revised framework reflects developments since 2017: the arrival of highly effective GLP-1 weight-loss medications (semaglutide, tirzepatide, retatrutide), expanded endoscopic therapies (Fractyl Revita duodenal mucosal resurfacing, intragastric balloons, endoscopic sleeve gastroplasty), and broader use of bariatric surgery. The framework formalizes a multidisciplinary care model that treats medications, endoscopic procedures, and surgery as complementary rather than competing — and addresses the post-GLP-1 weight-regain question by positioning endoscopic 'gut reset' procedures as part of the standard treatment arsenal. The commentary frames the next era of obesity care as combining GLP-1 medications with personalized procedures and surgery for greater results.

Industry · View digest

Retatrutide vs Bariatric Surgery — 45.3% of TRIUMPH-1 12 mg Participants Reached ≥30% Weight Loss, Reframing Surgical Referral Conversation

TRIUMPH-1 reported 45.3% of participants on the 12 mg dose reached ≥30% weight loss — historically the threshold associated with bariatric surgery outcomes (sleeve gastrectomy averages 25-30%, Roux-en-Y gastric bypass 30-35% at 1-2 years). The data point is the most consequential single statistic from the TRIUMPH-1 readout because it reframes the bariatric-referral conversation that anchors severe-obesity care. For patients with BMI 35-40 with comorbidities (the broadest bariatric-eligible population), pharmacological 30% weight loss closely approximates the surgical outcome without the irreversible anatomical changes, perioperative mortality (~0.1% gastric bypass), nutritional-deficiency monitoring requirements, or psychiatric adjustment patterns that follow bariatric procedures. Bariatric surgery centers' patient-referral volume began softening in 2024-2025 as Wegovy and Zepbound scaled; retatrutide's TRIUMPH-1 data accelerates that trend. The American Society for Metabolic and Bariatric Surgery (ASMBS) and the Obesity Society will likely revisit referral algorithms ahead of retatrutide's late-2027 launch.